Central line-associated bloodstream infection (CLABSI) occurrence is arguably 100% preventable, yet central venous access device (CVAD) related infections have a 12-25% mortality rate in the ICU setting1. One to 2 of every 8 patients who develop CLABSI don’t survive. In the webinar, 18 Months of Sticking to it: Dedicated team site care using gum mastic…
Lee Steere (RN, CRNI, VA-BC) holds national certification in Certified Registered Nurse Infusion as well as Vascular Access Board Certification. An RN for 21 years, he is the Manager of IV Therapy Services at Hartford Hospital in Harford, CT. He co-chairs the hospital’s Medical-Surgical Clinical Value Analysis Committee and is a member of their HAI…
“Up to 90% of hospitalized patients can require a PVAD during their stay, however, greater than 60% of PVADs fail due to dislodgement, phlebitis, occlusion, infiltration, or infection.”¹ PVAD infections are so prevalent that the topic “Infections from Peripherally Inserted IV Lines” became number 9 in the ECRI Institute’s 2019 Top 10 Patient Safety Concerns.…
Our newest edition of 3 Questions With… 3 Questions With… features some of the finest thought leaders in healthcare specialties such as Infection Prevention, Vascular Access, Surgical Care and more. These experts answer questions on the latest insights, evidence and current practices. For our newest 3 Questions With… Eloquest Healthcare is proud to feature Jack…
Our newest edition of 3 Questions With… 3 Questions With… features some of the finest thought leaders in healthcare specialties such as Infection Prevention, Vascular Access, Surgical Care and more. These experts answer questions on the latest insights, evidence and current practices. For our newest 3 Questions With… Eloquest Healthcare is proud to feature Russell…
We are excited to launch a new production, a video series entitled, “3 Questions With…” 3 Questions With… features some of the finest thought leaders in healthcare specialties such as Infection Prevention, Vascular Access, Surgical Care and more. These experts answer questions on the latest insights, evidence and current practices. For our premier 3 Questions…
The 33rd Annual Association for Vascular Access (AVA) Scientific Meeting will be held at Caesars Palace in Las Vegas—and Eloquest Healthcare will be there in the Exhibit Hall at Booth #318! AVA 2019 will occur from October 4th – 7th (pre-conference workshops are on October 3rd). The four-day meeting has a packed schedule with general…
The US Centers for Disease Control and Prevention (CDC) and The Infusion Nurses Society (INS) agree that vascular access device (VAD) dressing integrity is a critical factor for the prevention of hospital-acquired infection.1,2 Russell Nassof, JD, founder of RiskNomics, discusses the importance of common sense in evidenced-based medicine, the issue of dressing disruption, the prominence…
Vascular Access Devices (VADs) are more prevalent than ever, with some reports estimating that at any point in time there may be 5 million patients living with a VAD.[1] These patients may either be in the hospital receiving care or at home receiving longterm care, and while VADs offer flexibility to patients, VADs still have…
The public health burden associated with catheter‐related bloodstream infection (CRBSI*) is substantial. A publication reviewing the qualitative and quantitative evidence supporting the use of Mastisol® Liquid Adhesive for the reduction of CRBSI can be downloaded here. In this blog, we’ll review the important findings detailed in this publication. CRBSI vs CLABSI These two…